ID

27259

Description

111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01445054

Link

https://clinicaltrials.gov/show/NCT01445054

Keywords

Versions (1)
  1. 11/6/17 11/6/17 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 6, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT01445054

English

Eligibility Breast Cancer NCT01445054

1 forms  
Criteria
Description

Criteria

participant must have histological confirmation of primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
Description

Primary malignant neoplasm | Neoplasm Metastasis | Exception Melanoma | Exception Basal cell carcinoma | Exception Sarcoma | Exception Lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C1306459
UMLS CUI [2]
C0027627
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025202
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007117
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1261473
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0024299
primary tumor or metastatic focus must be 1.5cm or greater in diameter as established by palpation, ultrasound, mammography, ct or mri.
Description

Primary malignant neoplasm Diameter | Focus metastatic Diameter | Palpation | Ultrasonography | Mammography | CT | MRI

Data type

boolean

Alias
UMLS CUI [1,1]
C1306459
UMLS CUI [1,2]
C1301886
UMLS CUI [2,1]
C0205234
UMLS CUI [2,2]
C1522484
UMLS CUI [2,3]
C1301886
UMLS CUI [3]
C0030247
UMLS CUI [4]
C0041618
UMLS CUI [5]
C0024671
UMLS CUI [6]
C0040405
UMLS CUI [7]
C0024485
participant must be 18 years or older.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
availability of tumor tissue (either from the initial primary tumor or from current tumor lesion) for performing ihc or fish analysis for her2/neu (erb2)
Description

Primary malignant neoplasm Tumor tissue Available | Neoplasm Lesion Tumor tissue Available | HER2/Neu Status Immunohistochemistry | HER2/Neu Status FISH

Data type

boolean

Alias
UMLS CUI [1,1]
C1306459
UMLS CUI [1,2]
C0475358
UMLS CUI [1,3]
C0470187
UMLS CUI [2,1]
C0027651
UMLS CUI [2,2]
C0221198
UMLS CUI [2,3]
C0475358
UMLS CUI [2,4]
C0470187
UMLS CUI [3,1]
C1512413
UMLS CUI [3,2]
C0021044
UMLS CUI [4,1]
C1512413
UMLS CUI [4,2]
C0162789
chemistry and cbc parameters: serum creatinine less than or equal to 1.4mg/dl. sgot and sgpt less than or equal to 3 times of the upper limits of normal; total bilirubin, of less than or equal to 2 times the upper limits of normal or 3.0 mg/dl in patients with gilbert s syndrome; platelet count must be greater than 100,00.
Description

Chemistry | Complete Blood Count | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Gilbert Disease | Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0151339
UMLS CUI [2]
C0009555
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0201836
UMLS CUI [6]
C1278039
UMLS CUI [7]
C0017551
UMLS CUI [8]
C0032181
ecog performance score of 0 or 1.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
ability to provide informed consent.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
negative serum pregnancy test (within 48 hours of imaging agent injection) in women of child bearing age and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of (111)indium trastuzumab if participant is of child bearing age.
Description

Childbearing Potential Serum pregnancy test negative | Imaging Agent Injection | Childbearing Potential Contraceptive methods | Contraception, Barrier | Sexual Abstinence | Exception Hormonal contraception | Indium 111 Trastuzumab Injection

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430061
UMLS CUI [2,1]
C1512628
UMLS CUI [2,2]
C1533685
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [4]
C0004764
UMLS CUI [5]
C0036899
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C2985296
UMLS CUI [7,1]
C1881194
UMLS CUI [7,2]
C1533685
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known allergy to trastuzumab.
Description

Hypersensitivity trastuzumab

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0728747
pregnant or lactating women.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
participants for whom enrollment would significantly delay (greater than 2 weeks) the scheduled standard of care therapy.
Description

Enrollment | Delay Standard therapy Scheduled

Data type

boolean

Alias
UMLS CUI [1]
C1516879
UMLS CUI [2,1]
C0205421
UMLS CUI [2,2]
C2936643
UMLS CUI [2,3]
C0205539
participants with an active second malignancy (excluding treated basal cell skin carcinoma).
Description

Second Cancer | Exception Basal cell carcinoma Treated

Data type

boolean

Alias
UMLS CUI [1]
C0751623
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1522326
history of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis).
Description

Heart Diseases | Myocardial Infarction | Cardiac Arrhythmia Treatment required for | Valvular disease Symptomatic | Cardiomyopathy | Pericarditis

Data type

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0027051
UMLS CUI [3,1]
C0003811
UMLS CUI [3,2]
C0332121
UMLS CUI [4,1]
C3258293
UMLS CUI [4,2]
C0231220
UMLS CUI [5]
C0878544
UMLS CUI [6]
C0031046
participants with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
Description

Comorbidity Interferes with Clinical Trial Procedure | Comorbidity Interferes with Research results | Mental disorders Interfere with Clinical Trial Procedure | Mental disorders Interfere with Research results

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0008976
UMLS CUI [1,4]
C0184661
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0683954
UMLS CUI [3,1]
C0004936
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0008976
UMLS CUI [3,4]
C0184661
UMLS CUI [4,1]
C0004936
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0683954
participants with severe claustrophobia.
Description

Claustrophobia Severe

Data type

boolean

Alias
UMLS CUI [1,1]
C0008909
UMLS CUI [1,2]
C0205082
a participant who needs a nuclear medicine scan other than a pet scan as part of their work-up cannot enroll until these scans have been completed.
Description

Radionuclide Imaging Completed | Work up | Exception Positron-Emission Tomography

Data type

boolean

Alias
UMLS CUI [1,1]
C0034606
UMLS CUI [1,2]
C0205197
UMLS CUI [2]
C0750430
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0032743
gamma-camera table restrictions preclude scanning participants greater than 350 lbs (160 kg)
Description

Gamma Camera Scanning System Restriction | Body Weight Limited

Data type

boolean

Alias
UMLS CUI [1,1]
C0810610
UMLS CUI [1,2]
C0443288
UMLS CUI [2,1]
C0005910
UMLS CUI [2,2]
C0439801
with the exception of at13387 and pu-h71, and ad5f35her2ectm transduced autologous dendritic cell vaccine participants cannot have received another experimental drug within 14 days prior to or during study enrollment.
Description

Investigational New Drugs | Exception AT 13387 | Exception PU-H71 | Exception Autologous dendritic cell/adenovirus HER-2 vaccine

Data type

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C2830135
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C3502086
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1831756
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT01445054

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Primary malignant neoplasm | Neoplasm Metastasis | Exception Melanoma | Exception Basal cell carcinoma | Exception Sarcoma | Exception Lymphoma
Item
participant must have histological confirmation of primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
boolean
C1306459 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0025202 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1261473 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0024299 (UMLS CUI [6,2])
Primary malignant neoplasm Diameter | Focus metastatic Diameter | Palpation | Ultrasonography | Mammography | CT | MRI
Item
primary tumor or metastatic focus must be 1.5cm or greater in diameter as established by palpation, ultrasound, mammography, ct or mri.
boolean
C1306459 (UMLS CUI [1,1])
C1301886 (UMLS CUI [1,2])
C0205234 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C1301886 (UMLS CUI [2,3])
C0030247 (UMLS CUI [3])
C0041618 (UMLS CUI [4])
C0024671 (UMLS CUI [5])
C0040405 (UMLS CUI [6])
C0024485 (UMLS CUI [7])
Age
Item
participant must be 18 years or older.
boolean
C0001779 (UMLS CUI [1])
Primary malignant neoplasm Tumor tissue Available | Neoplasm Lesion Tumor tissue Available | HER2/Neu Status Immunohistochemistry | HER2/Neu Status FISH
Item
availability of tumor tissue (either from the initial primary tumor or from current tumor lesion) for performing ihc or fish analysis for her2/neu (erb2)
boolean
C1306459 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,3])
C0027651 (UMLS CUI [2,1])
C0221198 (UMLS CUI [2,2])
C0475358 (UMLS CUI [2,3])
C0470187 (UMLS CUI [2,4])
C1512413 (UMLS CUI [3,1])
C0021044 (UMLS CUI [3,2])
C1512413 (UMLS CUI [4,1])
C0162789 (UMLS CUI [4,2])
Chemistry | Complete Blood Count | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Gilbert Disease | Platelet Count measurement
Item
chemistry and cbc parameters: serum creatinine less than or equal to 1.4mg/dl. sgot and sgpt less than or equal to 3 times of the upper limits of normal; total bilirubin, of less than or equal to 2 times the upper limits of normal or 3.0 mg/dl in patients with gilbert s syndrome; platelet count must be greater than 100,00.
boolean
C0151339 (UMLS CUI [1])
C0009555 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0017551 (UMLS CUI [7])
C0032181 (UMLS CUI [8])
ECOG performance status
Item
ecog performance score of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
ability to provide informed consent.
boolean
C0021430 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative | Imaging Agent Injection | Childbearing Potential Contraceptive methods | Contraception, Barrier | Sexual Abstinence | Exception Hormonal contraception | Indium 111 Trastuzumab Injection
Item
negative serum pregnancy test (within 48 hours of imaging agent injection) in women of child bearing age and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of (111)indium trastuzumab if participant is of child bearing age.
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C1512628 (UMLS CUI [2,1])
C1533685 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0004764 (UMLS CUI [4])
C0036899 (UMLS CUI [5])
C1705847 (UMLS CUI [6,1])
C2985296 (UMLS CUI [6,2])
C1881194 (UMLS CUI [7,1])
C1533685 (UMLS CUI [7,2])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity trastuzumab
Item
known allergy to trastuzumab.
boolean
C0020517 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Enrollment | Delay Standard therapy Scheduled
Item
participants for whom enrollment would significantly delay (greater than 2 weeks) the scheduled standard of care therapy.
boolean
C1516879 (UMLS CUI [1])
C0205421 (UMLS CUI [2,1])
C2936643 (UMLS CUI [2,2])
C0205539 (UMLS CUI [2,3])
Second Cancer | Exception Basal cell carcinoma Treated
Item
participants with an active second malignancy (excluding treated basal cell skin carcinoma).
boolean
C0751623 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
Heart Diseases | Myocardial Infarction | Cardiac Arrhythmia Treatment required for | Valvular disease Symptomatic | Cardiomyopathy | Pericarditis
Item
history of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis).
boolean
C0018799 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0003811 (UMLS CUI [3,1])
C0332121 (UMLS CUI [3,2])
C3258293 (UMLS CUI [4,1])
C0231220 (UMLS CUI [4,2])
C0878544 (UMLS CUI [5])
C0031046 (UMLS CUI [6])
Comorbidity Interferes with Clinical Trial Procedure | Comorbidity Interferes with Research results | Mental disorders Interfere with Clinical Trial Procedure | Mental disorders Interfere with Research results
Item
participants with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
boolean
C0009488 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0184661 (UMLS CUI [1,4])
C0009488 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0683954 (UMLS CUI [2,3])
C0004936 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0008976 (UMLS CUI [3,3])
C0184661 (UMLS CUI [3,4])
C0004936 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0683954 (UMLS CUI [4,3])
Claustrophobia Severe
Item
participants with severe claustrophobia.
boolean
C0008909 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Radionuclide Imaging Completed | Work up | Exception Positron-Emission Tomography
Item
a participant who needs a nuclear medicine scan other than a pet scan as part of their work-up cannot enroll until these scans have been completed.
boolean
C0034606 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0750430 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0032743 (UMLS CUI [3,2])
Gamma Camera Scanning System Restriction | Body Weight Limited
Item
gamma-camera table restrictions preclude scanning participants greater than 350 lbs (160 kg)
boolean
C0810610 (UMLS CUI [1,1])
C0443288 (UMLS CUI [1,2])
C0005910 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
Investigational New Drugs | Exception AT 13387 | Exception PU-H71 | Exception Autologous dendritic cell/adenovirus HER-2 vaccine
Item
with the exception of at13387 and pu-h71, and ad5f35her2ectm transduced autologous dendritic cell vaccine participants cannot have received another experimental drug within 14 days prior to or during study enrollment.
boolean
C0013230 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C2830135 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3502086 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1831756 (UMLS CUI [4,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial